{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:33:33Z","timestamp":1790159613956,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.bone.2010.03.006","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T04:43:23Z","timestamp":1268714603000},"page":"12-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites"],"prefix":"10.1016","volume":"47","author":[{"given":"Monica M.","family":"Reinholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn P.","family":"Zinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Reinholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Jonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Kitzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Bruzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Negron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla K.","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie K.","family":"Arendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Croatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Sanchez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Sebesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri","family":"L\u00f6nnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl A.","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Spelsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry B.F. (Hal)","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Karpeisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma L.","family":"Lingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20 Pt 2","key":"10.1016\/j.bone.2010.03.006_bib1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"20 Pt 2","key":"10.1016\/j.bone.2010.03.006_bib2","doi-asserted-by":"crossref","first-page":"6209s","DOI":"10.1158\/1078-0432.CCR-06-1213","article-title":"Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bone.2010.03.006_bib4","first-page":"408","article-title":"Bisphosphonates for malignancy-related bone disease: current status, future developments","volume":"V14","author":"Body","year":"2006","journal-title":"Support Care Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.bone.2010.03.006_bib5","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.breast.2007.10.005","article-title":"Bisphosphonates: reducing the risk of skeletal complications from bone metastasis","volume":"16","author":"Costa","year":"2007","journal-title":"Breast"},{"issue":"2 Suppl 6","key":"10.1016\/j.bone.2010.03.006_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/sonc.2001.30704","article-title":"Unmet needs in metastatic bone disease and its complications: is progress possible?","volume":"28","author":"Hortobagyi","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bone.2010.03.006_bib7","unstructured":"Karpeisky MY, Padyukova NS, Mikhailov SN, Dixon HBF, Tzeitline G 2001 Bisphosphonate conjugates and methods of making and using the same. United States patent US 6, 214, 812 B1. MBC Research, Inc., Boulder, CO, US."},{"key":"10.1016\/j.bone.2010.03.006_bib8","unstructured":"Karpeisky MY, Padyukova NS, Mikhailov SN, Dixon HBF, Tzeitline G 2004 Bisphosphonate conjugates and methods of making and using the same. United States patent US 6, 750, 340 B2. MBC Research, Inc., Boulder, CO, US."},{"issue":"11","key":"10.1016\/j.bone.2010.03.006_bib9","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1021\/jo800317e","article-title":"Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5\u2032-beta, gamma-methylene and 5\u2032-beta, gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine","volume":"73","author":"Ora","year":"2008","journal-title":"J Org Chem"},{"issue":"6 Suppl 4","key":"10.1016\/j.bone.2010.03.006_bib10","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminoncol.2007.10.003","article-title":"Emerging strategies in bone health management for the adjuvant patient","volume":"34","author":"Coleman","year":"2007","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.bone.2010.03.006_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.bone.2010.03.006_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2010.03.006_bib13","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"10.1016\/j.bone.2010.03.006_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bone.2010.03.006_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/bcr412","article-title":"Direct effects of bisphosphonates on breast cancer cells","volume":"4","author":"Senaratne","year":"2002","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.bone.2010.03.006_bib16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bone.2010.03.006_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/0929867033368529","article-title":"In vitro and in vivo antitumor effects of bisphosphonates","volume":"10","author":"Clezardin","year":"2003","journal-title":"Curr Med Chem"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1014418017382","article-title":"Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue","volume":"71","author":"Reinholz","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"6 Suppl 21","key":"10.1016\/j.bone.2010.03.006_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/sonc.2002.37420","article-title":"The antitumor potential of bisphosphonates","volume":"29","author":"Clezardin","year":"2002","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.bone.2010.03.006_bib20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.bone.2010.03.006_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1523-1755.2005.00439.x","article-title":"MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: pathophysiologic correlates","volume":"68","author":"Pittock","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.bone.2010.03.006_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1006689719505","article-title":"A novel orthotopic model of breast cancer metastasis to bone","volume":"17","author":"Lelekakis","year":"1999","journal-title":"Clin Exp Metastasis"},{"issue":"13","key":"10.1016\/j.bone.2010.03.006_bib23","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl 11","key":"10.1016\/j.bone.2010.03.006_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0093-7754(01)90225-8","article-title":"Preclinical models of bone metastases","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin Oncol"},{"issue":"12 Suppl","key":"10.1016\/j.bone.2010.03.006_bib25","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","article-title":"Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma","volume":"88","author":"Yoneda","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bone.2010.03.006_bib26","first-page":"866","article-title":"Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6","volume":"10","author":"Westendorf","year":"1996","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bone.2010.03.006_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4049\/jimmunol.159.1.487","article-title":"A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth","volume":"159","author":"Jelinek","year":"1997","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.bone.2010.03.006_bib28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2010.03.006_bib29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MED.0b013e3282f15419","article-title":"Local effects of malignancy on bone","volume":"14","author":"Brown","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","article-title":"Crosstalk between cancer cells and bone microenvironment in bone metastasis","volume":"328","author":"Yoneda","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"10.1016\/j.bone.2010.03.006_bib31","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2174\/1381612023393585","article-title":"Bisphosphonates as a foundation of drug delivery to bone","volume":"8","author":"Uludag","year":"2002","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1039\/B512310K","article-title":"\u2018Magic bullets\u2019 for bone diseases: progress in rational design of bone-seeking medicinal agents","volume":"36","author":"Zhang","year":"2007","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bone.2010.03.006_bib33","series-title":"Bisphosphonates in Bone Disease","author":"Fleisch","year":"2000"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","article-title":"Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption","volume":"42","author":"Ezra","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"10.1016\/j.bone.2010.03.006_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00003088-200342100-00001","article-title":"Bone as an effect compartment: models for uptake and release of drugs","volume":"42","author":"Stepensky","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"10.1016\/j.bone.2010.03.006_bib36","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003088-200342150-00002","article-title":"Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents","volume":"42","author":"Hirabayashi","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20134","key":"10.1016\/j.bone.2010.03.006_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/10426509508042521","article-title":"Synthesis of gem-bisphosphonic doxorubicinconjugates","volume":"101","author":"Fabulet","year":"1995","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"issue":"1","key":"10.1016\/j.bone.2010.03.006_bib38","first-page":"105","article-title":"Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate","volume":"37","author":"Hosain","year":"1996","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.bone.2010.03.006_bib39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0223-5234(93)90043-E","article-title":"Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma","volume":"28","author":"Sturtz","year":"1993","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00389236","article-title":"Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma","volume":"111","author":"Wingen","year":"1986","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1\u20132","key":"10.1016\/j.bone.2010.03.006_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199809059253","article-title":"Anti-tumour activity of bisphosphonates in human myeloma cells","volume":"32","author":"Shipman","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bone.2010.03.006_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0145-2126(00)00087-4","article-title":"A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells","volume":"25","author":"Takahashi","year":"2001","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.bone.2010.03.006_bib43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.03.006_bib44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2008.10.047","article-title":"Inhibition of bone resorption and growth of breast cancer in the bone microenvironment","volume":"44","author":"Buijs","year":"2009","journal-title":"Bone"},{"issue":"21","key":"10.1016\/j.bone.2010.03.006_bib45","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bone.2010.03.006_bib46","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.bone.2010.03.006_bib47","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.bone.2010.03.006_bib48","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.3747\/co.v15i0.205","article-title":"A primer of bone metastases management in breast cancer patients","volume":"15","author":"Petrut","year":"2008","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.bone.2010.03.006_bib49","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.bone.2010.03.006_bib50","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2165\/0003495-200868180-00010","article-title":"Zoledronic acid: a review of its use in breast cancer","volume":"68","author":"Lyseng-Williamson","year":"2008","journal-title":"Drugs"},{"issue":"415 Suppl","key":"10.1016\/j.bone.2010.03.006_bib51","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1097\/01.blo.0000092981.12414.7b","article-title":"Metastatic breast cancer: overview of treatment","author":"Ali","year":"2003","journal-title":"Clin Orthop Relat Res"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210004990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210004990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:37:20Z","timestamp":1762659440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328210004990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S8756328210004990"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.03.006","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2010.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}